SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is currently trending as investors debate whether the stock has hit a bottom, with many pointing to recent insider buying and high-profile endorsements as potential catalysts for a turnaround. However, community sentiment remains deeply divided, as traders express significant frustration over persistent price weakness and the stock's failure to maintain momentum.

ZIM Integrated Shipping Services Ltd. engages in the provision of shipping and logistics services. It offers shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. The company was founded on June 7, 1945 and is headquartered in Haifa, Israel.

Zim Integrated Shipping Services Ltd

ZIM is trending due to a recently announced $4.2 billion acquisition by Hapag-Lloyd at $35 per share, sparking intense community debate over the deal's viability, the potential for a bidding war, and the impact of the Israeli government's 'golden share' on final approval. Investors are actively discussing the arbitrage opportunity presented by the price gap between the current market value and the buyout offer, while weighing risks related to ongoing labor strikes and geopolitical tensions in the Middle East.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is driving massive market-wide anticipation as investors brace for earnings results that serve as a crucial barometer for the sustainability of the AI infrastructure supercycle. The community is intensely debating whether the stock will break its trend of post-earnings selling or trigger a wider market rally, with discourse heavily focused on potential guidance surprises, supply chain factors, and hyperscaler capital expenditure trends.

Target Corp. engages in the operation and ownership of general merchandise stores. It offers food and general merchandise, clothing and household goods, electronics, and toys. Its brands include A New Day, All in Motion, Art Class, Auden, AVA & VIV, Boots and Barkley, Brightroom, Bullseye's Playground, Casaluna, Cat & Jack, Cloud Island, Colsie, dealworthy, Embark, Everspring, Favorite Day, Figmint, Future Collective, Gigglescape, Good & Gather, Goodfellow & Co, Hearth & Hand with Magnolia, Heyday, Hyde & EEK! Boutique, JoyLab, Kindfull, Kona Sol, Made By Design, Market Pantry, Mondo Llama, More Than Magic, Opalhouse, Open Story, Original Use, Pillowfort, Project 62, Room Essentials, Shade & Shore, Smartly, Smith & Hawken, Sonia Kashuk, Spritz, Sun Squad, Threshold, Universal Thread, up&up, Wild Fable, Wondershop, Xhilaration, California Roots, Casa Cantina, The Collection, Headliner, Jingle & Mingle, Rosé Bae, Photograph, SunPop, and Wine Cube. The company was founded by George Draper Dayton in 1902 and is headquartered in Minneapolis, MN.

Target Corp

Target is gaining momentum as investors react positively to the company's upbeat fiscal forecasts and a strategic $2 billion turnaround plan aimed at reinvigorating growth through store expansions and enhanced digital capabilities. The retail community is actively debating whether this performance signals a definitive bottom for the stock or if persistent inflationary pressures on consumer spending will ultimately hinder the company's long-term recovery.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following the FDA's acceptance of a supplemental BLA for ANKTIVA in bladder cancer, with investors closely watching the January 2027 PDUFA date as a catalyst for potential label expansion. Community discussions are centered on high short interest, the perceived undervaluation of the drug's potential, and ongoing debates regarding the FDA's regulatory timelines compared to positive real-world clinical data.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

Silver is experiencing heightened volatility and intense community debate as participants argue whether the recent pullback is a systemic collapse driven by rising bond yields and geopolitical shifts or a strategic buying opportunity for long-term holders. While short-sellers are betting on a continued decline, many retail investors remain convinced that structural supply deficits and inflationary pressures will force a rebound, leading to heated clashes between those calling for a structural bear market and those accumulating physical positions.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is experiencing a surge in investor interest and bullish momentum following optimistic commentary from the CEO regarding the survival data of its REGAL Phase 3 clinical trial. The community is actively discussing the potential for an imminent short squeeze and institutional accumulation as they wait for the 80th trial event, with many viewing the company's immunotherapy platform as a major candidate for future valuation growth.

Keysight Technologies, Inc. engages in the provision of electronic design and test solutions that are used in the design, development, manufacture, installation, deployment, validation, optimization, and secure operation of electronics systems to communications, networking, and electronics industries. It operates through the Communications Solutions Group (CSG) and Electronic Industrial Solutions Group (EISG) segments. The CSG segment serves customers spanning the global commercial communications and aerospace, defense, and government end markets. The EISG segment offers test and measurement solutions across electronic industrial end markets, focusing on applications in the automotive, and energy industry and measurement solutions for semiconductor design and manufacturing, consumer electronics, education, and general electronics manufacturing. The company was founded by William R. Hewlett and David Packard in 1937 and is headquartered in Santa Rosa, CA.

Keysight Technologies Inc

Keysight Technologies is seeing heightened investor attention following a fiscal quarter earnings report that topped expectations, with the community actively debating whether the company's strong order momentum and AI infrastructure exposure represent a sustained uptrend or a cyclical cycle. While some traders are focused on short-term price action and potential gap fills, institutional sentiment remains supportive as multiple firms have raised their price targets.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

CAVA Group shares are rallying as the market responds to a strong earnings report that featured impressive same-store sales growth and a raised fiscal outlook. The community is actively discussing the company's resilience in a tough economic climate, with many investors debating its premium valuation relative to restaurant peers as the stock maintains momentum.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance is trending as shareholders react to the Warner Bros. Discovery merger approval and ongoing institutional buying, even as the stock faces downward pressure and skepticism regarding executive compensation and long-term value. Community discourse remains deeply divided between long-term holders frustrated by the stock's recent performance and optimistic investors betting on post-merger synergies, AI-driven efficiencies, and an expanded sports and content portfolio.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Fulcrum Therapeutics (NASDAQ:FULC) Rating Increased to Sell at Wall Street Zen

Wall Street Zen raised Fulcrum Therapeutics from a "strong sell" rating to a "sell" rating in a research note on Saturday...

HC Wainwright Issues Optimistic Estimate for FULC Earnings

Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) - Research analysts at HC Wainwright boosted their Q2 2026 earnings per share (EPS) estimates for shares of Fulcrum Therapeutics in a research...

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) have earned an average recommendation of "Moderate Buy" from the ten analysts that are currently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, one has i...

Fulcrum Therapeutics (NASDAQ:FULC) Posts Quarterly Earnings Results, Beats Estimates By $0.06 EPS

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) posted its earnings results on Monday. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.06...

Fulcrum Therapeutics (NASDAQ:FULC) Shares Gap Down - Time to Sell?

Fulcrum Therapeutics (NASDAQ:FULC) Shares Gap Down - Time to Sell...

Fulcrum Therapeutics Q1 Earnings Call Highlights

Fulcrum Therapeutics (NASDAQ:FULC) highlighted new clinical and corporate progress during its first-quarter 2026 financial results and business update call, with management emphasizing positive Phase...

Fulcrum Therapeutics Q1 2026 Earnings Call: Complete Transcript

Fulcrum Therapeutics (NASDAQ:FULC) Stock Price Down 4.9% - Time to Sell?

Fulcrum Therapeutics (NASDAQ:FULC) Shares Down 4.9% - Here's What Happened...

Short Interest in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Grows By 41.1%

Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) was the target of a significant growth in short interest during the month of March. As of March 31st, there was short interest totaling...

Fulcrum Therapeutics (NASDAQ:FULC) Stock Rating Lowered by Wall Street Zen

Wall Street Zen downgraded Fulcrum Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Sunday...

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015, and is headquartered in Cambridge, MA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.28	--	--	N/A
Q1 '26	-$0.29	-$0.25	15.04%	BEAT
Q4 '25	-$0.30	-$0.31	-3.65%	MISSED
Q3 '25	-$0.29	-$0.31	-5.53%	MISSED
Q2 '25	-$0.29	-$0.28	3.45%	BEAT

FULC
Fulcrum Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q1 '26

Historical Earnings

Latest FULC News

FULCFulcrum Therapeutics Inc